This decision has been based on the recognition as an orphan drug granted by the
Malignant mesothelioma is a tumor arising from the mesothelial cells of the pleural, peritoneal, or pericardial lining of the lung and is often associated with asbestos exposure, usually with a very poor prognosis at diagnosis. There is currently no cure for most malignant mesotheliomas. For this reason, the objective of current cancer treatments (surgery, radiotherapy and chemotherapy) is to reduce or eliminate symptoms, as well as prolong progression-free survival (PFS) and/or overall survival (OS). It is estimated that the incidence of this type of cancer may increase in the coming years, after exposure to asbestos, since there is a long latency period after exposure before a Malignant Mesothelioma forms.
Contact:
Tel: +34 91 846 6000
Fax: 91 846 6001
Email: pharmamar@pharmamar.com
(C) 2022 Electronic News Publishing, source